Novel Associations of VKORC1 Variants with Higher Acenocoumarol Requirements

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Anton, Ana Isabel ^a   Cerezo Manchado, Juan J ^a   Padilla, Jose ^a   Perez Andreu, Virginia ^a   Corral, Javier ^a   Vicente, Vicente ^a   Roldan, Vanessa ^a   Gonzalez Conejero, Rocio ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; VKORC1 GENE; DNA SEQUENCE; DOSE RESPONSE; GENETICS; MOLECULAR GENETICS; ORAL DRUG ADMINISTRATION; PHENOTYPE; STATISTICAL MODEL;

ACENOCOUMAROL; ADMINISTRATION, ORAL; ANTICOAGULANTS; BASE SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; LINEAR MODELS; MOLECULAR SEQUENCE DATA; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; VITAMIN K EPOXIDE REDUCTASES;

EID: 84877872515     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064469     Document Type: Article

References (33)

1. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, et al. (2012) Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines 9thed. Chest 141: e637S-68S.
2. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, et al. (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113: 784-792.
3. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331.
4. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. (2009) A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose. PLoS Genet 5: e1000433.
5. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, van Schaik RH, et al. (2009) A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18: 3758-3768.
6. Daly AK, (2010) Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11: 241-6.
7. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
8. Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE, (2011) Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 57: 612-618.
9. Kurnik D, Loebstein R, Halkin H, Gak E, Almog S, (2009) 10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal. Pharmacogenomics 10: 1955-1965.
10. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, et al. (2011) Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12: 113-124.
11. U.S. Food and Drug Administration (2007) Press Release: FDA approves updated warfarin (Coumadin) prescribing information. Rockville, MD: FDA. Available: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01684.html. Accessed 2008 May 19.
12. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, et al. (2012) Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e152S-84S.
13. Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, et al. (2009) Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 10: 632-642.
14. Pérez-Andreu V, Roldán V, Antón AI, García-Barberá N, Corral J, et al. (2009) Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113: 4977-4979.
15. van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, et al. (2011) EU-PACT Study Group Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32: 1909-1917.
16. Verde Z, Ruiz JR, Santiago C, Valle B, Bandrés F, et al. (2010) A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One 5: e11210.
17. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, et al. (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109: 2477-2480.
18. Watzka M, Geisen C, Bevans CG, Sittinger K, Spohn G, et al. (2011) Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost 9: 109-118.
19. Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, et al. (2008) Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 6: 1663-1670.
20. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9: 1445-1458.
21. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, et al. (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112: 1013-1021.
22. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, et al. (2011) Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 90: 625-629.
23. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E, (2008) VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111: 3903-3904.
24. Scott SA, Edelmann L, Kornreich R, Desnick RJ, (2008) Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82: 495-500.
25. Shuen AY, Wong BY, Fu L, Selby R, Cole DE, (2012) Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem 45: 397-401.
26. Bodin L, Perdu J, Diry M, Horellou MH, Loriot MA, (2008) Multiple genetic alterations in vitamin K epoxide reductase complex subunit 1 gene (VKORC1) can explain the high dose requirement during oral anticoagulation in humans. J Thromb Haemost 6: 1436-1439.
27. Rost S, Pelz HJ, Menzel S, MacNicoll AD, León V, et al. (2009) Novel mutations in the VKORC1 gene of wild rats and mice--a response to 50 years of selection pressure by warfarin? BMC Genet 10: 4-12.
28. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, et al. (2005) A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105: 645-649.
29. Mitchell C, Gregersen N, Krause A, (2011) Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12: 953-963.
30. Sauna ZE, Kimchi-Sarfaty C, (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12: 683-691.
31. King CR, Deych E, Milligan P, Eby C, Lenzini P, et al. (2010) Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 104: 750-754.
32. González-Conejero R, Corral J, Roldán V, Ferrer F, Sánchez-Serrano I, et al. (2007) The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost 5: 1701-1706.
33. Krumm N, Sudmant PH, Ko A, O'Roak BJ, Malig M, et al. (2012) Copy number variation detection and genotyping from exome sequence data. Genome Res 22: 1525-1532.